A research team from Massachusetts General Hospital has identified a significant target for immune-oncology therapy-tumor necrosis factor receptor type II (TNFR2). The inhibition of these receptors was found to induce the immune system of cancer patients to fight against the developing tumor.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer